Anticoagulation in Stent Intervention "MUSICA-2"
Active, not recruiting
Phase 4 Results N/AUpdate History
25 Feb '15 |
A location was updated in Badalona. New The overall status was removed for Hospital Germans Trias i Pujol. A location was updated in Hospitalet de Llobregat. New The overall status was removed for Hospital Universitari de Bellvitge. A location was updated in Sabadell. New The overall status was removed for Corporación Sanitaria Parc Taulí. A location was updated in Santander. New The overall status was removed for Hospital Marqués de Valdecilla. A location was updated in Majadahonda. New The overall status was removed for Hospital Puerta del Hierro. A location was updated in Barcelona. New The overall status was removed for Hospital Clínic de Barcelona. A location was updated in Barcelona. New The overall status was removed for Hospital Sant Pau. A location was updated in Barcelona. New The overall status was removed for Hospital Universitario Vall d'Hebron. A location was updated in Girona. New The overall status was removed for Hospital Dr.Josep Trueta. A location was updated in Madrid. New The overall status was removed for Hospital San Carlos. A location was updated in Madrid. New The overall status was removed for Hospital Universitario Gregorio Marañón. |
6 Oct '11 |
The Summary of Purpose was updated. New
Objective:
The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg
/ day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as
control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with
atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S.
Design:
Randomized, parallel, with two arms, blind evaluation by third parties.
Patients:
304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤
2), which requires prevention of thrombosis
Old
Objective:
The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg
/ day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as
control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with
atrial fibrillation, low-moderate risk of stroke (CHADS ? 2) who are undergoing PCI-S.
Design:
Randomized, parallel, with two arms, blind evaluation by third parties.
Patients:
304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ?
2), which requires prevention of thrombosis
|
View Trial Locations
Recruitment
- Enrollment: 304
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 11 locations, 1 country
Principal Investigators
- Antonia Sambola, MD Ph
asambola@yahoo.es 34932746000
- David García -Dorado, MD Ph